Fabian J Brunner,Christoph Waldeyer,Francisco Ojeda,Veikko Salomaa,Frank Kee,Susana Sans,Barbara Thorand,Simona Giampaoli,Paolo Brambilla,Hugh Tunstall-Pedoe,Marie Moitry,Licia Iacoviello,Giovanni Veronesi,Guido Grassi,Ellisiv B Mathiesen,Stefan Söderberg,Allan Linneberg,Hermann Brenner,Philippe Amouyel,Jean Ferrières,Abdonas Tamosiunas,Yuriy P Nikitin,Wojciech Drygas,Olle Melander,Karl-Heinz Jöckel,David M Leistner,Jonathan E Shaw,Demosthenes B Panagiotakos,Leon A Simons,Maryam Kavousi,Ramachandran S Vasan,Robin P F Dullaart,S Goya Wannamethee,Ulf Risérus,Steven Shea,James A de Lemos,Torbjørn Omland,Kari Kuulasmaa,Ulf Landmesser,Stefan Blankenberg,Multinational Cardiovascular Risk Consortium,Tanja Zeller,Jukka Kontto,Satu Männistö,Andres Metspalu,Karl Lackner,Philipp Wild,Annette Peters,Christa Meisinger,Chiara Donfrancesco,Stefano G Signorini,Maris Alver,Mark Woodward,Francesco Gianfagna,Simona Costanzo,Tom Wilsgaard,Mats Eliasson,Torben Jørgensen,Henry Völzke,Marcus Dörr,Matthias Nauck,Ben Schöttker,Thiess Lorenz,Nataliya Makarova,Raphael Twerenbold,Jean Dallongeville,Annette Dobson,Sofia Malyutina,Andrzej Pajak,Gunnar Engström,Martin Bobak,Börge Schmidt,Tuija Jääskeläinen,Teemu Niiranen,Pekka Jousilahti,Graham Giles,Allison Hodge,Jens Klotsche,Dianna J Magliano,Magnus N Lyngbakken,Kristian Hveem,Christos Pitsavos,Emelia J Benjamin,Stephan J L Bakker,Peter Whincup,M Kamran Ikram,Martin Ingelsson,Wolfgang Koenig

Abstract:Background: The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment. Methods: In this risk-evaluation and risk-modelling study, we used Multinational Cardiovascular Risk Consortium data from 19 countries across Europe, Australia, and North America. Individuals without prevalent cardiovascular disease at baseline and with robust available data on cardiovascular disease outcomes were included. The primary composite endpoint of atherosclerotic cardiovascular disease was defined as the occurrence of the coronary heart disease event or ischaemic stroke. Sex-specific multivariable analyses were computed using non-HDL cholesterol categories according to the European guideline thresholds, adjusted for age, sex, cohort, and classical modifiable cardiovascular risk factors. In a derivation and validation design, we created a tool to estimate the probabilities of a cardiovascular disease event by the age of 75 years, dependent on age, sex, and risk factors, and the associated modelled risk reduction, assuming a 50% reduction of non-HDL cholesterol. Findings: Of the 524 444 individuals in the 44 cohorts in the Consortium database, we identified 398 846 individuals belonging to 38 cohorts (184 055 [48·7%] women; median age 51·0 years [IQR 40·7-59·7]). 199 415 individuals were included in the derivation cohort (91 786 [48·4%] women) and 199 431 (92 269 [49·1%] women) in the validation cohort. During a maximum follow-up of 43·6 years (median 13·5 years, IQR 7·0-20·1), 54 542 cardiovascular endpoints occurred. Incidence curve analyses showed progressively higher 30-year cardiovascular disease event-rates for increasing non-HDL cholesterol categories (from 7·7% for non-HDL cholesterol <2·6 mmol/L to 33·7% for ≥5·7 mmol/L in women and from 12·8% to 43·6% in men; p<0·0001). Multivariable adjusted Cox models with non-HDL cholesterol lower than 2·6 mmol/L as reference showed an increase in the association between non-HDL cholesterol concentration and cardiovascular disease for both sexes (from hazard ratio 1·1, 95% CI 1·0-1·3 for non-HDL cholesterol 2·6 to <3·7 mmol/L to 1·9, 1·6-2·2 for ≥5·7 mmol/L in women and from 1·1, 1·0-1·3 to 2·3, 2·0-2·5 in men). The derived tool allowed the estimation of cardiovascular disease event probabilities specific for non-HDL cholesterol with high comparability between the derivation and validation cohorts as reflected by smooth calibration curves analyses and a root mean square error lower than 1% for the estimated probabilities of cardiovascular disease. A 50% reduction of non-HDL cholesterol concentrations was associated with reduced risk of a cardiovascular disease event by the age of 75 years, and this risk reduction was greater the earlier cholesterol concentrations were reduced. Interpretation: Non-HDL cholesterol concentrations in blood are strongly associated with long-term risk of atherosclerotic cardiovascular disease. We provide a simple tool for individual long-term risk assessment and the potential benefit of early lipid-lowering intervention. These data could be useful for physician-patient communication about primary prevention strategies. Funding: EU Framework Programme, UK Medical Research Council, and German Centre for Cardiovascular Research.

Lipoprotein insulin resistance score and mortality risk stratification in heart failure

Remnant Cholesterol Predicts Long-term Mortality of Patients with Metabolic Dysfunction-associated Fatty Liver Disease

HDL-C, Longitudinal Change and Risk of Mortality in a Chinese Cohort Study.

The Association between Baseline Serum Lipids and Mortality in Peritoneal Dialysis Patients

Development and Validation of a Protein Risk Score for Mortality in Heart Failure

Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort

Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study

Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy

Metabolic score for insulin resistance as a predictor of mortality in heart failure with preserved ejection fraction: results from a multicenter cohort study

HDL, apo a1 and long-term cardio-metabolic prognosis in statin-treated patients with suspected stable angina pectoris: a prospective cohort study

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study

Impaired HDL antioxidant and anti-inflammatory functions are linked to increased mortality in acute heart failure patients

Inflammation and cholesterol associated residual cardiovascular risk and its dependence on chronic kidney disease in statin treated patients with coronary artery disease

Circulating ketone bodies and mortality in heart failure: a community cohort study

Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium

Associations between remnant cholesterol levels and mortality in patients with diabetes

Synergistic effect of the commonest residual risk factors, remnant cholesterol, lipoprotein(a), and inflammation, on prognosis of statin-treated patients with chronic coronary syndrome

Associations of High Hdl Cholesterol Level with All-Cause Mortality in Patients with Heart Failure Complicating Coronary Heart Disease

Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study

Insulin resistance and chronic kidney disease progression, cardiovascular events, and death: findings from the chronic renal insufficiency cohort study

Lipid Profiles and Heart Failure Risk: Results from Two Prospective Studies